Beijing, Sept 3, 2026 — China’s National Medical Products Administration (NMPA) and General Administration of Customs (GACC) issued Announcement No. 84 of 2026, tightening import-export declaration requirements for psychotropic substances by adding three pharmaceutical compounds to the regulated catalog and publishing customs commodity codes for cross-border shipments, effective Oct 1, 2026.
Policy Snapshot
| Attribute | Detail |
|---|---|
| Issuers | NMPA; General Administration of Customs; Ministry of Public Security; National Health Commission |
| Document | Announcement on Declaration Requirements for Import and Export of Psychotropic Drugs (2026 No. 84) |
| Newly listed substances | Metomidate (excluding domestically approved formulations); an etomidate analog (excluding domestically approved formulations); solriamfetol |
| Effective date | Oct 1, 2026 |
| Legal basis | Drug Administration Law; Customs Law |
Key Provisions
- Expanded catalog — The NMPA, Ministry of Public Security, and National Health Commission jointly added metomidate, an etomidate analog, and solriamfetol to the medicinal psychotropic substances directory. Domestically approved formulations containing these compounds are exempted from the new controls.
- Customs codes — The announcement publishes reference customs commodity codes for the newly listed substances to facilitate import-export declarations.
- Declaration scope — The published commodity codes cover only a portion of regulated goods. Shippers must declare truthfully if actual imports or exports fall outside the specified code ranges.
- Enforcement — All cross-border movements of the listed substances must comply with the new declaration framework starting Oct 1, 2026.
Market Impact Analysis
The regulatory expansion targets new psychoactive substances and their analogs that have emerged as public health concerns, particularly etomidate derivatives that have seen misuse in non-medical settings. By exempting domestically approved formulations, regulators are drawing a sharp distinction between legitimate pharmaceutical supply chains and uncontrolled chemical flows, minimizing disruption to licensed manufacturers while closing loopholes for illicit trade.
For pharmaceutical importers and customs brokers, the Oct 1 effective date creates a narrow compliance window to update classification systems and train personnel on the new commodity codes. The explicit warning that codes cover only partial product ranges places the burden of accurate declaration squarely on traders, with misclassification risks carrying penalties under both drug control and customs regulations.
Solriamfetol’s inclusion is notable given its prior status as a prescription wakefulness agent; the new controls signal Beijing’s assessment that the compound requires stricter cross-border monitoring due to diversion potential.
Forward-Looking Statement
Industry analysts expect the NMPA to release supplementary implementation guidance before Oct 1, clarifying documentation requirements for legitimate pharmaceutical shipments and the specific exemption procedures for domestically approved formulations. Customs authorities are likely to intensify inspections of chemical and pharmaceutical cargo from key source regions starting in the fourth quarter. Trading companies and freight forwarders handling active pharmaceutical ingredients or finished psychotropic medicines should audit their commodity code databases immediately and establish verification protocols to ensure declarations capture all regulated substances, including analogs not explicitly named in the initial code list.-China Health Reform Pulse
Policy Source: https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260902092356142.html